Genomma Lab Internacional, S.A.B. de C.V. Announces CEO Changes
November 28, 2022 at 01:53 am EST
Share
Genomma Lab Internacional, S.A.B. de C.V. announces a leadership succession plan that positions the Company to continue driving profitable growth and delivering on the Company's vision, as CEO Jorge Brake has informed the Board of his intention to transition from the CEO role while maintaining active involvement in the Company's future. Mr. Brake will be appointed Active Vice Chairman of the Board of Directors, pending approval at Genomma's next Annual General Shareholders Meeting to be held in April 2023. In accordance with the Company's leadership succession plan, Mr. Rodrigo Herrera, Chairman of the Board informs that Marco Sparvieri, currently Genomma Lab's Chief Operating Officer, will succeed Jorge Brake as Chief Executive Officer. Genomma's succession plan ensures a six month transition period during which Mr. Brake and Mr. Sparvieri will be collaborating closely.
Marco Sparvieri is a proven and seasoned business leader with an excellent broad based skill base and a deep understanding of the Company and its brands, who has developed a strong long term relationship with customers and suppliers. All of which ensures his success in his new role as CEO. He began his tenure at Genomma initiating a transformational period during which he led the development of new Commercial and Supply Chain models, enabling the Company to expand its geographical and multi channel presence while integrating new products within its portfolio.
As Chief Operating Officer, Mr. Sparvieri took an integral role in the subsequent phase of Genomma's 2018 transformation period, and has been key at leading the Company's strategy in the areas of Innovation, Go to Market, Supply Chain and Organization/People development over the last four years. During this period, his role and responsibilities have continued to expand behind a well-designed development plan. Mr. Sparvieri joined Genomma Lab in 2014 after a successful 20 year career with Procter & Gamble, working in several geographies and roles.
He holds a degree in Industrial Engineering from the University of Buenos Aires, Argentina and has participated in several executive programs with top business education institutions.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
